CytoDyn Completes Enrolment In Phase 2 CLOVER Trial For Leronlimab In Treating Colorectal Cancer

CytoDyn completed enrollment in its Phase 2 CLOVER trial of leronlimab in combination with trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer. Completion of enrollment is a positive operational milestone for the clinical-stage oncology company, but it does not include efficacy or safety data. The news is likely to be incremental for the stock rather than a major catalyst.

Analysis

CytoDyn completed enrollment in its Phase 2 CLOVER trial of leronlimab in combination with trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer. Completion of enrollment is a positive operational milestone for the clinical-stage oncology company, but it does not include efficacy or safety data. The news is likely to be incremental for the stock rather than a major catalyst.